WAL0921 / Walden Biosci - LARVOL DELTA

Study of WAL0921 in Patients With Glomerular Kidney Diseases (clinicaltrials.gov) - P2 | N=96 | Recruiting | Sponsor: Walden Biosciences | Trial completion date: Mar 2026 ➔ Jun 2027 | Trial primary completion date: Oct 2025 ➔ Mar 2027

Trial completion date • Trial primary completion date • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Study of WAL0921 in Patients With Glomerular Kidney Diseases (clinicaltrials.gov) - P2 | N=96 | Recruiting | Sponsor: Walden Biosciences | Not yet recruiting ➔ Recruiting

Enrollment open • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Study of WAL0921 in Patients With Glomerular Kidney Diseases (clinicaltrials.gov) - P2 | N=96 | Not yet recruiting | Sponsor: Walden Biosciences

New P2 trial • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease

Single Ascending Dose Study of WAL0921 in Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Walden Biosciences | Recruiting ➔ Completed

Trial completion

Single, Ascending Dose Study of WAL0921 in Healthy Subjects (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Walden Biosciences

New P1 trial